These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Association of Sustained Blood Pressure Control with Lower Risk for High-Cost Multimorbidities Among Medicare Beneficiaries in ALLHAT. Bowling CB; Sloane R; Pieper C; Luciano A; Davis BR; Simpson LM; Einhorn PT; Oparil S; Muntner P J Gen Intern Med; 2021 Aug; 36(8):2221-2229. PubMed ID: 33564944 [TBL] [Abstract][Full Text] [Related]
6. Systolic blood pressure levels among adults with hypertension and incident cardiovascular events: the atherosclerosis risk in communities study. Rodriguez CJ; Swett K; Agarwal SK; Folsom AR; Fox ER; Loehr LR; Ni H; Rosamond WD; Chang PP JAMA Intern Med; 2014 Aug; 174(8):1252-61. PubMed ID: 24935209 [TBL] [Abstract][Full Text] [Related]
7. Visit-to-Visit Glycemic Variability and Risks of Cardiovascular Events and All-Cause Mortality: The ALLHAT Study. Echouffo-Tcheugui JB; Zhao S; Brock G; Matsouaka RA; Kline D; Joseph JJ Diabetes Care; 2019 Mar; 42(3):486-493. PubMed ID: 30659073 [TBL] [Abstract][Full Text] [Related]
8. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Muntner P; Davis BR; Cushman WC; Bangalore S; Calhoun DA; Pressel SL; Black HR; Kostis JB; Probstfield JL; Whelton PK; Rahman M; Hypertension; 2014 Nov; 64(5):1012-21. PubMed ID: 25259745 [TBL] [Abstract][Full Text] [Related]
9. The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Kronish IM; Lynch AI; Oparil S; Whittle J; Davis BR; Simpson LM; Krousel-Wood M; Cushman WC; Chang TI; Muntner P Hypertension; 2016 Jul; 68(1):39-45. PubMed ID: 27217410 [TBL] [Abstract][Full Text] [Related]
10. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Rahman M; Ford CE; Cutler JA; Davis BR; Piller LB; Whelton PK; Wright JT; Barzilay JI; Brown CD; Colon PJ; Fine LJ; Grimm RH; Gupta AK; Baimbridge C; Haywood LJ; Henriquez MA; Ilamaythi E; Oparil S; Preston R; Clin J Am Soc Nephrol; 2012 Jun; 7(6):989-1002. PubMed ID: 22490878 [TBL] [Abstract][Full Text] [Related]
11. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. Buckley LF; Dixon DL; Wohlford GF; Wijesinghe DS; Baker WL; Van Tassell BW Diabetes Care; 2017 Dec; 40(12):1733-1738. PubMed ID: 28947569 [TBL] [Abstract][Full Text] [Related]
12. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA; 2000 Apr; 283(15):1967-75. PubMed ID: 10789664 [TBL] [Abstract][Full Text] [Related]
13. Association of Blood Pressure Classification in Young Adults Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Cardiovascular Events Later in Life. Yano Y; Reis JP; Colangelo LA; Shimbo D; Viera AJ; Allen NB; Gidding SS; Bress AP; Greenland P; Muntner P; Lloyd-Jones DM JAMA; 2018 Nov; 320(17):1774-1782. PubMed ID: 30398601 [TBL] [Abstract][Full Text] [Related]
15. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763 [TBL] [Abstract][Full Text] [Related]